09:35:33 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-23 Kvartalsrapport 2024-Q2
2024-05-17 Ordinarie utdelning CHOSA 0.00 SEK
2024-05-10 Kvartalsrapport 2024-Q1
2024-02-29 Bokslutskommuniké 2023
2023-11-10 Kvartalsrapport 2023-Q3
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-29 Ordinarie utdelning CHOSA 0.00 SEK
2023-05-26 Årsstämma 2023
2023-05-05 Kvartalsrapport 2023-Q1
2023-02-27 Bokslutskommuniké 2022
2023-01-11 Extra Bolagsstämma 2022
2022-11-11 Kvartalsrapport 2022-Q3
2022-08-26 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning CHOSA 0.00 SEK
2022-05-18 Årsstämma 2022
2022-05-05 Kvartalsrapport 2022-Q1
2022-02-11 Bokslutskommuniké 2021
2021-11-12 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-05-20 Ordinarie utdelning CHOSA 0.00 SEK
2021-05-19 Årsstämma 2021
2021-05-05 Kvartalsrapport 2021-Q1
2021-02-12 Bokslutskommuniké 2020
2020-11-13 Kvartalsrapport 2020-Q3
2020-08-28 Kvartalsrapport 2020-Q2
2020-05-13 Ordinarie utdelning CHOSA 0.00 SEK
2020-05-12 Årsstämma 2020
2020-05-05 Kvartalsrapport 2020-Q1
2020-02-11 Bokslutskommuniké 2019
2019-11-15 Kvartalsrapport 2019-Q3
2019-09-25 Extra Bolagsstämma 2019
2019-08-30 Kvartalsrapport 2019-Q2
2019-05-10 Ordinarie utdelning CHOSA 0.00 SEK
2019-05-09 Årsstämma 2019
2019-05-08 Kvartalsrapport 2019-Q1
2019-02-12 Bokslutskommuniké 2018
2018-11-16 Kvartalsrapport 2018-Q3
2018-08-31 Kvartalsrapport 2018-Q2
2018-05-11 Ordinarie utdelning CHOSA 0.00 SEK
2018-05-09 Årsstämma 2018
2018-05-09 Kvartalsrapport 2018-Q1
2018-02-13 Bokslutskommuniké 2017
2017-11-03 Kvartalsrapport 2017-Q3
2017-08-31 Kvartalsrapport 2017-Q2
2017-05-11 Ordinarie utdelning CHOSA 0.00 SEK
2017-05-10 Årsstämma 2017
2017-05-10 Kvartalsrapport 2017-Q1
2017-02-09 Bokslutskommuniké 2016
2017-01-10 Extra Bolagsstämma 2017
2016-10-27 Kvartalsrapport 2016-Q3
2016-08-31 Kvartalsrapport 2016-Q2
2016-05-10 Kvartalsrapport 2016-Q1
2016-05-10 Årsstämma 2016

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriBioteknik
CHOSA Oncology är ett danskt-svenskt bioteknikbolag. Bolaget har utvecklat iCIP-plattformen, som inkluderar en liposomal formulering av cisplatin (LiPlaCis) och det diagnostiska verktyget (DRP) som upptäcker patienter som bör ha mest nytta av cisplatinbehandlingen. De nyligen uppnådda kliniska fas 2b-resultaten innebär att bolaget rustar upp affärsutvecklingen för att hitta partners för partnerskap eller handelsavtal.
2021-12-09 08:42:00

RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today on December 9[th], 2021, that its Data & Safety Monitoring Committee (DSMC) has conducted a planned interim safety review of its clinical phase IIb trial in prostate cancer, known as BRaVac. All patients have now been recruited into the study. The safety profile of RV001 (onilcamotide) was considered excellent, and the DSMC concluded that the trial can continue without modifications.

RhoVac started the clinical phase IIb trial (BRaVac) with the company's drug candidate, RV001, (onilcamotide) late 2019, in prostate cancer patients with a biochemical recurrence (a rise in PSA) after curative intent therapy. In November of 2020, RhoVac was awarded Fast Track Designation by the FDA for its drug candidate in this cancer indication. RhoVac currently estimates finalising the study and presenting results in the first half of the 2022. The objective of the study is to show that RV001 (onilcamotide) can significantly prevent or delay disease progression in these patients, something for which no standard therapy is available today. As planned, an interim safety review was conducted by the DSMC last week, and no unexpected adverse events have been identified, confirming excellent safety, in concurrence with the previous DSMC conclusions on BRaVac, as well as with the findings of the phase I/II study, including follow-up studies. And therefore, the study continues without modifications.

RhoVac CEO, Anders Månsson, comments: "RhoVac has handled its study recruitment well in spite of the difficulties circumstances brought about by the covid pandemic. We had no reason to anticipate anything but a clean safety review. Nevertheless, it is great to get further confirmation that our drug has a safety profile that makes it suitable for treating symptomless cancer patients who have already undergone local curative intent therapy, with an aim to prevent cancer recurrence and metastatic disease. An effective cancer vaccine with this profile could fulfil a huge unmet medical need in prostate cancer as well as in on other common cancers".

This disclosure contains information that RhoVac is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 09-12-2021 08:42 CET.